相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
Jianjie Li et al.
JOURNAL OF THORACIC DISEASE (2021)
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer A systematic review and meta-analysis
Ying Kong et al.
MEDICINE (2021)
The Case for Maintenance Pemetrexed Plus Bevacizumab
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting
Katherine B. Winfree et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Feiyu Shan et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Corey J. Langer et al.
CLINICAL LUNG CANCER (2017)
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
Domenico Galetta et al.
CLINICAL LUNG CANCER (2015)
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer
Ralph G. Zinner et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Phase 2, Randomized, Open-Label Study of Ramucirumab in Combination With First-Line Pemetrexed and Platinum Chemotherapy in Patients With Nonsquamous, Advanced/Metastatic Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CANCER (2015)
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F. Barlesi et al.
ANNALS OF ONCOLOGY (2014)
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Jean-Louis Pujol et al.
CLINICAL LUNG CANCER (2014)
PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
Fabrice Barlesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2012)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
Pemetrexed disodium: A novel Antifolate clinically active against multiple solid tumors
AR Hanauske et al.
ONCOLOGIST (2001)
分享论文
